ZARZA We are Zarza, the prestigious firm behind major projects in information technology.

TMO EPM / Hemato H9J

Por: TMO EPM / Hemato H9J

Podcast de discussão de assuntos em Hematologia do Transplante de Medula Óssea da Escola Paulista de Medicina (UNIFESP) e da Hematologia do Hospital 9 de Julho - DASA

65 episodios disponibles

Últimos episódios do podcast TMO EPM / Hemato H9J

65 - Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma 05/11/2025

64 - Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin 02/11/2025

63 - Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT 01/09/2025

62 - Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation 10/08/2025

61 - Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study 04/08/2025

60 - Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826 27/07/2025

59 - Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation 23/07/2025

58 - Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised,double-blind, placebo controlled, phase 3 study 13/07/2025

57 - A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adults 06/07/2025

56 - Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities 29/06/2025

55 - Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation 22/06/2025

54 - Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial 02/06/2025

53 - Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma 02/05/2025

52 - Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia 29/04/2025

51 - Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia 13/04/2025

50 - Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia 07/04/2025

49 - Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation 18/03/2025

48 - Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma 16/03/2025

47 - Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma 11/03/2025

46 - Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study 29/12/2024

1 2 3 4 Siguiente › Última »